Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Enact Holdings Down Over 6%, on Track for Largest Percent Decrease Since February 2023 -- Data Talk

Enact Holdings Down Over 6%, on Track for Largest Percent Decrease Since February 2023 -- Data Talk

Dow JonesDow Jones2026/09/30 19:28

Enact Holdings Inc. (ACT) is currently at $43.40, down $3.04 or 6.55%

--Would be lowest close since June 23, 2026, when it closed at $43.32

--On pace for largest percent decrease since Feb. 7, 2023, when it fell 7.21%

--Currently down 11 of the past 12 days

--Currently down five consecutive days; down 9.11% over this period

--Longest losing streak since Sept. 22, 2026, when it fell for six straight trading days

--Worst five day stretch since the five days ending April 8, 2025, when it fell 9.35%

--Down 9.96% month-to-date

--Up 9.49% year-to-date

--Down 13.32% from its all-time closing high of $50.07 on Sept. 14, 2026

--Up 14.63% from 52 weeks ago (Oct. 1, 2025), when it closed at $37.86

--Down 13.32% from its 52-week closing high of $50.07 on Sept. 14, 2026

--Up 24.25% from its 52-week closing low of $34.93 on Oct. 29, 2025

--Traded as low as $42.83; lowest intraday level since June 23, 2026, when it hit $42.83

--Down 7.77% at today's intraday low; largest intraday percent decrease since May 4, 2023, when it fell as much as 7.78%

All data as of 3:25:12 PM ET

Source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

September 30, 2026 15:28 ET (19:28 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.

NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.

华尔街见闻•2026/11/09 22:12